Eugene Schneider net worth and biography

Eugene Schneider Biography and Net Worth

Dr. Schneider is executive vice president and chief clinical development and operations officer of Ionis Pharmaceuticals. As a member of our executive leadership team, Dr. Schneider oversees all stages of clinical development of Ionis’ antisense medicines across the company’s therapeutic franchises. Dr. Schneider joined Ionis in December 2013 as executive director, clinical development and became vice president, clinical development, severe and rare diseases in April 2015, senior vice president, head of clinical development in August 2018 and executive vice president, chief clinical development officer in January 2021.

Dr. Schneider has two decades of experience in clinical development primarily in the rare diseases space. Prior to joining Ionis, Dr. Schneider was senior medical director at both Synageva BioPharma and Biovail Technologies Ltd.

Dr. Schneider received his medical degree from University of Medicine and Dentistry of New Jersey and completed his training in Pediatric and Adolescent Medicine at Robert Wood Johnson University Hospital in New Brunswick, New Jersey.

What is Eugene Schneider's net worth?: The estimated net worth of Eugene Schneider is at least $1.59 million as of January 12th, 2024. Dr. Schneider owns 38,170 shares of Ionis Pharmaceuticals stock worth more than $1,587,490 as of April 27th. This net worth estimate does not reflect any other investments that Dr. Schneider may own. Learn More about Eugene Schneider's net worth.
How do I contact Eugene Schneider?: The corporate mailing address for Dr. Schneider and other Ionis Pharmaceuticals executives is 2855 GAZELLE COURT, CARLSBAD CA, 92010. Ionis Pharmaceuticals can also be reached via phone at (760) 931-9200 and via email at [email protected]. Learn More on Eugene Schneider's contact information.
Has Eugene Schneider been buying or selling shares of Ionis Pharmaceuticals?: Eugene Schneider has not been actively trading shares of Ionis Pharmaceuticals over the course of the past ninety days. Most recently, Eugene Schneider sold 8,000 shares of the business's stock in a transaction on Friday, January 12th. The shares were sold at an average price of $53.50, for a transaction totalling $428,000.00. Following the completion of the sale, the executive vice president now directly owns 38,170 shares of the company's stock, valued at $2,042,095. Learn More on Eugene Schneider's trading history.
Who are Ionis Pharmaceuticals' active insiders?: Ionis Pharmaceuticals' insider roster includes C. Bennett (EVP), Spencer Berthelsen (Director), Brian Birchler (EVP), Onaiza Cadoret-Manier (EVP), Breaux Castleman (Director), Stanley Crooke (Chairman), Allene Diaz (Director), Richard Geary (EVP), Elizabeth Hougen (CFO), Joseph Klein, III (Director), Brett Monia (CEO), Frederick Muto (Director), Patrick O'Neil (EVP), B. Parshall, Esq. (Director), Eugene Schneider (EVP), and Eric Swayze (EVP). Learn More on Ionis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ionis Pharmaceuticals?: During the last year, insiders at the sold shares 28 times. They sold a total of 291,805 shares worth more than $14,352,782.01. The most recent insider tranaction occured on April, 16th when EVP Joseph Baroldi sold 4,006 shares worth more than $166,649.60. Insiders at Ionis Pharmaceuticals own 2.7% of the company. Learn More about insider trades at Ionis Pharmaceuticals.
Information on this page was last updated on 4/16/2024.

Eugene Schneider Insider Trading History at Ionis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/12/2024	Sell	8,000	$53.50	$428,000.00	38,170

Eugene Schneider Buying and Selling Activity at Ionis Pharmaceuticals

Ionis Pharmaceuticals Company Overview

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Today's Range

Now: $41.59

$41.36

$42.28

50 Day Range

MA: $43.33

$40.68

$47.41

2 Week Range

Now: $41.59

$34.32

$54.44

Volume

556,043 shs

Average Volume

1,129,417 shs

Market Capitalization

$6.06 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39

These AI trades triggered this morning (545% return)

From Prosper Trading Academy | Ad

If you think a market crash is possible in 2024, I don't know why you're not using this yet.

Click Here To Get Your Free Copy